Aspire Biopharma Holdings, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kraig T. Higginson
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 23150 Fashion Drive Estero FL United States of America 33928
- IPO Date
- Feb 20, 2025
- CIK
- 0001847345
- Website
- aspirebiolabs.com
- Similar Companies
- Business
- Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) is an early-stage biopharmaceutical company that develops and markets disruptive patent-pending sublingual drug delivery technology designed for rapid absorption into the bloodstream, bypassing the gastrointestinal tract to enhance bioavailability, speed of onset, and efficacy while reducing side effects; the platform applies to active pharmaceutical ingredients, nutraceuticals, and supplements across categories including analgesics such as Instaprin, a soluble pH-neutral fast-acting sublingual aspirin for cardiology emergencies and pain management that inhibits platelet aggregation in under two minutes; melatonin sleep aids; vitamins D, E, and K; testosterone; semaglutide; anti-nausea and anti-psychotic products; erectile dysfunction drugs; seizure medications; and caffeine supplements like BUZZ BOMB, a 50mg single-dose sublingual pre-workout product in flavors including Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha, marketed through its wholly owned subsidiary Buzz Bomb Caffeine Company LC via e-commerce at buzzbombcaffeine.com. Founded in 2021 and headquartered at 23150 Fashion Drive, Suite 232, Estero, Florida, the company operates primarily in the United States within the biotechnology and pharmaceuticals sector, targeting multi-billion-dollar markets for reformulated approved drugs and consumer supplements with customers spanning healthcare providers, pharmaceutical partners, athletes, fitness enthusiasts, and general consumers. Recent developments include completion of a business combination with PowerUp Acquisition Corp. in February 2025 enabling Nasdaq listing under ASBP and improved capital access; appointment of Kraig Higginson as interim CEO in July 2025; filing of an omnibus U.S. patent application and plans for five to ten additional patents by Q1 2026; submission of a Pre-IND meeting request to the FDA in Q3 2025 for sublingual high-dose aspirin with responses expected by January 2026 and NDA targeted for H1 2026; expansion of the scientific team with Mark J. Jaroszeski, PhD; participation in CPHI Frankfurt yielding licensing discussions; positive bioavailability trial data for sublingual aspirin; a manufacturing agreement with SupraNaturals for two million servings of BUZZ BOMB ahead of Christmas 2025 availability; launch of influencer marketing and e-commerce for BUZZ BOMB; and distribution of over 30,000 samples at FitCon and FitExpo events.
Aspire Biopharma Issues Shareholder Letter
Aspire Biopharma's BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of Members
Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio
Aspire Biopharma Announces $5.0 Million Share Repurchase Program
Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition
Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo
Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue
Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion
Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion
Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director
Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026
Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack
Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief
Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship
Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements
Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))
Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))
Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements